Savara Inc. (NASDAQ:SVRA) is one of the best stocks under $5 with highest upside potential. On October 23, Citizens JMP lifted its price target on Savara Inc. (NASDAQ:SVRA) to $11 from $8 while keeping an Outperform rating on the shares. The firm told investors in a research note that its pulmonologist survey shows solid demand for Molbreevi, with 60% of those surveyed expressing an inclination to use it. This, according to Citizens JMP, should mean blockbuster sales, with Savara Inc. (NASDAQ:SVRA) set t ...

Group 1 - Savara Inc. has been identified as a promising healthcare penny stock, with Guggenheim raising its price target from $8 to $11 while maintaining a Buy rating, following a 16% stock rally year to date [1][2] - The price target increase is supported by positive developments regarding the company's Biologics License Application (BLA), with potential FDA approval expected by mid-next year [2][3] - Savara is transitioning its primary drug manufacturing from GEMA to Fujifilm Diosynth Biotechnologies, which is significant due to Fujifilm's strong FDA track record and new claims indicating a 50% increase in the number of patients in the US with autoimmune pulmonary alveolar proteinosis (aPAP) [3][4] Group 2 - Savara Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases, particularly its lead candidate, molgramostim, an inhaled GM-CSF for aPAP [4]